{"raw_mentions": "Among other properties, compounds of the invention have been found to be potent inhibitors of M<sub>3</sub> muscarinic receptor activity. \nAccordingly, in a specific embodiment, the invention is directed to compounds of formula I having an inhibition dissociation constant (Kj) for the M<sub>3</sub> receptor subtype of less than or equal to 10 nM, as determined, for example, by an in vitro radioligand displacement assay. \nIn one embodiment, compounds of the invention have a Kj value for the M<sub>3</sub> receptor subtype of less than or equal to 5 nM."}
{"final_json": [{"molecule_name": null, "protein_target_name": "M3 muscarinic receptor", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kj", "value": "<=10", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "M3 receptor subtype", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kj", "value": "<=5", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nSaturation binding studies for determining K^ values of the radioligand were performed using L-[N- methyl-<sup>3</sup>H] scopolamine methyl chloride ([<sup>3</sup>H]-NMS) (TRK666, 84.0 Ci/mmol, Amersham Pharmacia Biotech, Buckinghamshire, England) at concentrations ranging from 0.001 nM to 20 nM.\nThe test compounds were initially dissolved to a concentration of 400 \u03bcM in dilution buffer and then serially diluted 5x with dilution buffer to final concentrations ranging from 10 pM to 100 \u03bcM.\nDisplacement assays for determination of K, values of test compounds were performed with [<sup>3</sup>H]-NMS at 1 nM and eleven different test compound concentrations."}
{"final_json": [{"molecule_name": "[<sup>3</sup>H]-NMS", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K^", "value": null, "unit": null}, {"molecule_name": "test compounds", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "[<sup>3</sup>H]-NMS", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K,", "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* Compounds of the invention are expected to have a K; value of less than about 10 nM for blockade of oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-Kl cells expressing the hM2 receptor, when tested in this or a similar assay.\n* The EC9<sub>0</sub> value (effective concentration for 90% maximal response) for stimulation of [<sup>35</sup>S]GTPyS binding by the agonist oxotremorine is determined in each experiment.\n* To measure oxotremorine inhibition of adenylyl cyclase (AC) activity, 25 \u03bcL forskolin (25 \u03bcM final concentration diluted in dPBS), 25 \u03bcL diluted oxotremorine, and 50 \u03bcL cells are added to agonist assay wells.\n* To measure the ability of a test compound to block oxotremorine-inhibited AC activity, 25 \u03bcL forskolin and oxotremorine (25 \u03bcM and 5 \u03bcM final concentrations, respectively, diluted in dPBS) 25 \u03bcL diluted test compound, and 50 \u03bcL cells are added to remaining assay wells."}
{"final_json": [{"molecule_name": null, "protein_target_name": "hM2 receptor", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K", "value": "<10", "unit": "nM"}, {"molecule_name": "oxotremorine", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC90", "value": null, "unit": null}, {"molecule_name": "forskolin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "25", "unit": "\u03bcM"}, {"molecule_name": "oxotremorine", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "5", "unit": "\u03bcM"}]}
